Jury Sides With Endo And Impax On 2014 Opana Antitrust Suit
Opana ER Purchasers Claimed $102m Endo Payment ‘Effectively Guaranteed’
Endo and Impax have received a favorable jury verdict after a 2010 patent-litigation settlement between the pair over Endo’s Opana ER was alleged to have been “an anticompetitive scheme that restrained competition,”
You may also be interested in...
FTC v. Endo: Exclusive Licenses, ‘Supracompetitive Prices’ Are Protected By Patent Laws
In an unsealed redacted opinion dismissing FTC’s complaint, district judge says Endo’s agreement with Impax, which left it the sole marketer of oxymorphone ER, falls within the bounds of anticompetitive activity protected by patent laws.
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.
Sandoz Reveals New Headquarters Post Spin, Mid-2024 Date Outlined
Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.